An Open-label Randomized Multicenter Phase III Clinical Study Comparing Safety and Efficacy of Algeron (Cepeginterferon Alfa-2b) and and PegIntron (Peginterferon Alfa-2b) in Combination With Ribavirin as Combined Treatment of Chronic Hepatitis C in Human Immunodeficiency Virus-1 Infected Patients

NCT02103439 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

140

Enrollment

INDUSTRY

Sponsor class

Conditions

Hepatitis
Hepatitis C
Hepatitis C/ Human Immunodeficiency Virus Coinfection

Interventions

DRUG: Algeron
DRUG: PegIntron

Sponsor

Biocad